HMP Global July 29, 2024
On June 26, the Center for Disease Control and Prevention (CDC) vaccine advisory group updated its recommendation for the use of the respiratory syncytial virus (RSV) vaccine in older adults. It now recommends that people ages 75 and older receive a single lifetime dose, and people ages 60 to 74 with certain underlying conditions—such as lung disease, cardiovascular disease, moderate or severe immune compromise, diabetes with end-organ damage, severe obesity, neurologic or neuromuscular conditions, advanced chronic kidney disease, liver disorders, and hematologic disorders—also receive a dose of the vaccine.
RSV is estimated to hospitalize 60 000 to 160 000 older adults each year. At the end of May, the Food and Drug Administration (FDA) approved the use of Moderna’s...
Today's Sponsors
Today's Sponsor